Cwm LLC Increases Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Cwm LLC lifted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 99.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,990 shares of the company’s stock after buying an additional 4,480 shares during the quarter. Cwm LLC’s holdings in Recursion Pharmaceuticals were worth $96,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of RXRX. Swiss National Bank raised its holdings in shares of Recursion Pharmaceuticals by 7.6% during the 1st quarter. Swiss National Bank now owns 94,300 shares of the company’s stock valued at $675,000 after buying an additional 6,700 shares during the period. Bank of New York Mellon Corp grew its stake in Recursion Pharmaceuticals by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock valued at $2,676,000 after purchasing an additional 6,294 shares in the last quarter. MetLife Investment Management LLC grew its stake in Recursion Pharmaceuticals by 55.4% during the 1st quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock valued at $458,000 after purchasing an additional 22,833 shares in the last quarter. Rhumbline Advisers grew its stake in Recursion Pharmaceuticals by 4.0% during the 1st quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock valued at $887,000 after purchasing an additional 4,818 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 8.1% during the 1st quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock valued at $47,338,000 after purchasing an additional 497,504 shares in the last quarter. 63.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on RXRX. The Goldman Sachs Group raised their price objective on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Wednesday, November 9th. SVB Leerink lowered their price objective on Recursion Pharmaceuticals from $10.00 to $9.00 and set a “market perform” rating for the company in a research note on Tuesday, October 25th.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 8,885 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, December 27th. The stock was sold at an average price of $7.25, for a total value of $64,416.25. Following the completion of the transaction, the director now owns 7,628,272 shares in the company, valued at approximately $55,304,972. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, COO Tina Marriott Larson sold 16,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $10.72, for a total value of $171,520.00. Following the sale, the chief operating officer now owns 205,107 shares of the company’s stock, valued at approximately $2,198,747.04. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 8,885 shares of the firm’s stock in a transaction that occurred on Tuesday, December 27th. The stock was sold at an average price of $7.25, for a total value of $64,416.25. Following the completion of the sale, the director now directly owns 7,628,272 shares in the company, valued at approximately $55,304,972. The disclosure for this sale can be found here. In the last quarter, insiders bought 297,727 shares of company stock worth $2,233,995 and sold 205,713 shares worth $1,947,057. Insiders own 22.25% of the company’s stock.

Recursion Pharmaceuticals Trading Up 5.5 %

Shares of RXRX opened at $9.18 on Wednesday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -6.37 and a beta of -0.47. The stock has a 50 day moving average of $8.86 and a 200-day moving average of $9.78. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $14.18.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01. The company had revenue of $13.16 million during the quarter, compared to analyst estimates of $6.43 million. Recursion Pharmaceuticals had a negative return on equity of 53.04% and a negative net margin of 860.34%. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.38 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.